You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. DESIGN OF A PROTON THERAPY DELIVERY SYSTEM

    SBC: Acctek Associates, Inc.            Topic: N/A

    N/A

    SBIR Phase I 1986 Department of Health and Human Services
  2. REAL TIME 3-DIMENSIONAL BRACHYTHERAPY GUIDANCE SYSTEM

    SBC: BURDETTE MEDICAL SYSTEMS, INC.            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  3. LONG RANGE COST ESTIMATE MODEL FOR SOCIAL SECURITY

    SBC: Actuarial Research Corporation            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  4. Classification of Breast Lesions In Ultrasound Imaging

    SBC: Advanced Applications            Topic: N/A

    We will develop a computer-assisted system to improve the ability of breast sonography to distinguifrom benign lesions. These are lesions originally detected by mammography and sent to ultrasound forThe lesions are biopsied when they are classified by ultrasound as solid or indeterminate, even thoubenign at biopsy. Because of the large numbers of breast biopsies being performed, even a small impro ...

    SBIR Phase I 1995 Department of Health and Human Services
  5. POLYETHYLENE GLYCOL ADDITION TO RECOMBINANT PROTEINS

    SBC: Advanced Genetic            Topic: N/A

    The long range objective of this proposal is to find mild, highly specific conditions for the targeted addition of polyethylene glycol to specific residues of recombinant proteins. Because proteins which have been modified by polyethylene glycol addition have increased serum persistence and decreased immunogenicity, this objective, if achieved, has the potential to decrease the frequency of paren ...

    SBIR Phase I 1997 Department of Health and Human Services
  6. FRACTAL DIMENSION FEATURES FOR MRI BREAST MASS ANALYSIS

    SBC: Alan Penn & Associates Inc            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  7. TRAINING SECONDARY PREVENTION OF FETAL ALCOHOL SYNDROME

    SBC: Alcohol Self-control Program            Topic: N/A

    N/A

    SBIR Phase I 1997 Department of Health and Human Services
  8. INTERFACE

    SBC: American Biotechnology Co            Topic: N/A

    A MAJOR OBJECTIVE OF THIS STUDY IS TO INVESTIGATE THE UTILITY OF A NEW AND INNOVATIVE LIQUID MICROCARRIER (MC) SYSTEM FOR CLONING AND PROPAGATING HUMAN TUMOR CELLS IN VITRO. THIS NEW PATENTED TECHNOLOGY IS AN OIL EMULSION OF DEFINED DROPLET SIZE (100 TO 200 MM) HAVING A SMOOTH, PLIABLE, AND TRANSPARENT SURFACE. THE PROTEIN AT THE OIL EMULSION INTERFACE CAN DIRECTLY SUPPORT THE GROWTH OF TRANSFORME ...

    SBIR Phase I 1986 Department of Health and Human Services
  9. THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS.

    SBC: AMT, INC.            Topic: N/A

    THE COMPLEX 4-CARBOXYPHTHALATO (1, 2-DIAMINOCYCLOHEXANE) PLATINUM (NSC 271674; DACH-PT) HAS UNDERGONE LIMITED CLINICAL TRIALS. DESIGNED AS AN ALTERNATIVE THERAPY TO CISPLATIN, IT HAS DEMONSTRATED SUBSTANTIALLY REDUCED TOXICITY AND ENHANCED ACTIVITY IN TUMORS RESISTANT TO CISPLATIN IN ANIMALS STUDIES, RESULTS CONFIRMED IN THE CLINIC. HEAVILY PRETREATED PHASE I AND PHASE II PATIENTS RESPONDING TO DA ...

    SBIR Phase I 1986 Department of Health and Human Services
  10. VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).

    SBC: Angiogen, Inc.            Topic: N/A

    VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S). THE IDENTIFICATION OF ONE OF THESE FACTORS AS "ANGIOGENIC COPPER" RAISES THE POSSIBILITY THAT COPPER CHELATORS CAN FUNCTION AS ANTIANGIOGENIC AGENTS. THE SPECIFIC AIMS OF THIS PHASE I S ...

    SBIR Phase I 1986 Department of Health and Human Services
US Flag An Official Website of the United States Government